Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealth Net Asfotase Alfa Coverage Update | OpenPay…
    Ask Trek AI about this page
    CurrentHealth NetPolicy CP PHAR.328

    Clinical Policy: Asfotase Alfa (Strensiq)

    Customize your policy alerts

    Sign up for Health Net Policy CP PHAR.328 alerts

    Get alerted when Policy CP PHAR.328 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governs medical necessity and prior authorization criteria for asfotase alfa (Strensiq) for perinatal/infantile- and juvenile-onset hypophosphatasia across commercial, HIM and Medicaid lines of business.

    Policy Summary
    PayerHealth Net
    PolicyAsfotase Alfa (Strensiq) clinical policy
    Policy CodePolicy CP PHAR.328
    Change TypeNo material change
    Effective DateMar 1, 2024
    Next Review DateNov 24, 2024
    Key ActionProvider must submit documentation (office chart notes, lab results or other clinical information) supporting that the member has met all approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Perinatal: 9 mg/kg/wk

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    maximum dosing
    Juvenile: 6 mg/kg/wkdose
    6–12 moauth length
    Boxed warningsafety
    J3490, C9399billing codes

    Coverage Criteria

    Initial Therapy

    Initial therapy covered when ALL of the following are met:

    Diagnosis of perinatal/infantile- or juvenile-onset HPP: Age of onset < 18 years with molecular genetic testing documenting a tissue non-specific alkaline phosphatase (ALPL) gene mutation.
    Clinical manifestations: History of at least one HPP clinical manifestation such as vitamin B6-dependent seizures; nephrocalcinosis with hypercalcemia/hypercalciuria; failure to thrive/growth failure/short stature; low bone mineral density with unexplained fractures; alveolar bone loss with premature loss of deciduous teeth; or skeletal abnormalities (e.g., craniosynostosis with increased intracranial pressure, rachitic chest deformity with respiratory compromise, limb deformity, compromised exercise capacity, delayed walking/gait abnormality).
    Prescriber and dosing requirements: Prescribed by or in consultation with an endocrinologist; dosing must not exceed 9 mg/kg/week for perinatal/infantile-onset HPP and 6 mg/kg/week for juvenile-onset HPP.

    Dose may be administered as 3 mg/kg SC three times per week or equivalent as specified in dosing guidance.

    Continuation Therapy

    Continuation therapy covered when:

    Eligibility for continuation: Member is currently receiving the medication via the benefit or has previously met initial approval criteria; OR member is covered under continuity-of-care regulations for their state/product.
    Clinical response requirement: Member demonstrates a positive clinical response to therapy, evidenced by improvement in one or more of: respiratory function; height velocity; skeletal manifestations (bone mineralization, bone formation/remodeling, fracture healing, correction of deformity); or motor function/mobility/gait.

    If request is for a dose increase, the new dose must not exceed 9 mg/kg/week for perinatal/infantile-onset or 6 mg/kg/week for juvenile-onset.

    Requests for indications that are not FDA-approved and are not specifically addressed in this policy are excluded unless the provider supplies adequate documentation of efficacy and safety in accordance with the applicable off‑label use policies (for example, CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, or CP.PMN.53 for Medicaid) or other evidence of coverage documents.

    When there is a conflict between this clinical policy and state Medicaid coverage provisions, the state Medicaid requirements take precedence. Providers must follow applicable state and federal requirements and the member’s evidence of coverage or other plan documents when those documents differ from this policy.

    Off‑label use requests for indications not FDA‑approved and not addressed in this policy may be denied if the submission does not include sufficient documentation of efficacy and safety per the payer’s off‑label use policies. Providers should follow the referenced off‑label policies and supply supporting clinical evidence to avoid denial.

    Initial Therapy

    Initial Therapy

    Initial approval criteria and dosing limits

    Diagnostic and clinical requirements: Must have diagnosis of perinatal/infantile- or juvenile-onset HPP supported by genetic testing or laboratory confirmation and at least one clinical manifestation consistent with HPP (see policy clinical manifestations).
    Prescriber requirement: Prescribed by or in consultation with an endocrinologist.
    Dosing limits: Dosing must not exceed 9 mg/kg/week for perinatal/infantile-onset HPP and 6 mg/kg/week for juvenile-onset HPP.

    Perinatal/infantile-onset dosing may be administered as up to 3 mg/kg SC three times per week (up to 9 mg/kg/week); juvenile-onset dosing may be administered as 2 mg/kg SC three times per week (6 mg/kg/week) or equivalent regimens noted in dosing guidance.

    Continuation / Renewal Criteria

    Continuation Therapy

    Requirements for renewal/continuation

    Continuation eligibility: Member is currently receiving the medication or previously met initial approval criteria, or continuity-of-care provisions apply.
    Evidence of clinical benefit: Documented positive response to therapy demonstrated by improvement in respiratory function, height velocity, skeletal manifestations (bone mineralization, fracture healing, deformity improvement), or motor function/mobility/gait on the re-authorization request.
    Dose change condition: If a dose increase is requested, the new dose must not exceed the maximums: 9 mg/kg/week for perinatal/infantile-onset or 6 mg/kg/week for juvenile-onset.

    Coding and Dosing

    HCPCS Codes referencedHCPCS
    J3490Unclassified drugs or biologicals (listed in policy)
    C9399Unclassified drugs or biologicals (listed in policy)
    Referenced HCPCS CodesHCPCS
    J3490Unclassified drugs or biologicals (HCPCS) - referenced
    C9399Unclassified drugs or biologicals (HCPCS) - referenced
    inv-08: Maximum weekly dose — perinatal/infantile-onset and juvenile-onset dosing limits
    Perinatal/infantile-onset maximumUp to 9 mg/kg per week (maximum dose) — may be administered as 3 mg/kg SC three times per week or equivalent; dose may be increased for lack of efficacy up to 9 mg/kg/week.
    Perinatal/infantile-onset typical regimenDosing regimen described as 6 mg/kg SC per week (various schedules permitted); maximum 9 mg/kg/week.
    Juvenile-onset maximumMaximum dose 6 mg/kg per week — commonly administered as 2 mg/kg three times per week or equivalent.
    inv-09: Approval duration (historical) — 6 months or to member's renewal date
    Medicaid/HIM (historical)Medicaid/HIM historically referenced ~6 months to 12 months depending on program; continuation guidance notes Medicaid/HIM typically 12 months for renewals.

    Provider Actions and Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Provider must submit documentation (such as office chart notes, laboratory results, genetic testing reports, and other clinical information) supporting the diagnosis and that the member meets all approval criteria. Requests should include prescribing provider specialty and rationale for therapy.

    • Include molecular genetic testing results (e.g., ALPL gene) when applicable
    • Include baseline laboratory indices (e.g., low serum alkaline phosphatase, elevated substrates such as pyridoxal 5'-phosphate or urinary inorganic pyrophosphate)
    • Provide clinical manifestations supporting the diagnosis (seizures, nephrocalcinosis, failure to thrive, skeletal abnormalities, dental findings, etc.)
    Note

    Provider Guidance

    Providers should follow this clinical policy as guidance for coverage determinations but must exercise their professional medical judgment. The clinical policy does not replace provider decision-making; supporting documentation must be submitted to demonstrate medical necessity.

    Site of Care

    Note

    Site of care — no explicit restriction stated

    No explicit site‑of‑care restriction is stated in this portion of the policy.

    Formulary / Step Therapy Routing

    ScenarioRequired routing / referenced policies
    Drug is on the formulary (commercial or health insurance marketplace) or on the PDL (Medicaid)Follow the no‑coverage / formulary criteria policy for the relevant line of business: CP.CPA.190 (commercial), HIM.PA.33 (health insurance marketplace), or CP.PMN.255 (Medicaid). If the drug recently had a label change not reflected in this policy, follow the referenced policy guidance as applicable.
    Drug is NOT on the formulary (commercial or health insurance marketplace) or NOT on the PDL (Medicaid)Follow the non‑formulary policy for the relevant line of business: CP.CPA.190 (commercial), HIM.PA.103 (health insurance marketplace), or CP.PMN.16 (Medicaid).
    Requested use (diagnosis, age, or dosing regimen) is not listed in this policy and criterion above does not applyRefer to the off‑label use policy for the relevant line of business: CP.CPA.09 (commercial), HIM.PA.154 (health insurance marketplace), or CP.PMN.53 (Medicaid).

    Background

    Hypophosphatasia (HPP) is a rare metabolic bone disease caused by loss‑of‑function mutations in the ALPL gene resulting in deficient tissue nonspecific alkaline phosphatase activity and accumulation of its substrates. The resulting biochemical abnormalities (for example, low serum alkaline phosphatase with elevated substrates such as pyridoxal 5'-phosphate and inorganic pyrophosphate) produce clinical manifestations including impaired bone mineralization, fractures, growth failure, respiratory compromise in severe forms, tooth loss, and neurologic features such as vitamin B6‑dependent seizures. Asfotase alfa (Strensiq) is a targeted enzyme replacement therapy — a tissue nonspecific alkaline phosphatase — approved to treat perinatal/infantile‑ and juvenile‑onset HPP to improve bone mineralization and related clinical outcomes.

    Definitions and Purpose

    inv-19: HPP / Asfotase alfa — drug indication and brief description
    Drug and brandAsfotase alfa (Strensiq)
    IndicationTreatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).
    Mechanism / descriptionRecombinant tissue nonspecific alkaline phosphatase (enzyme replacement) used to improve bone mineralization and HPP-related manifestations; dosing regimens and maximum weekly doses differ by age of onset.
    inv-20: Clinical policy purpose — guidance purpose and disclaimer
    Primary purposeProvide guidance to assist in making coverage decisions and administering benefits; not medical advice and not a guarantee of payment.
    Scope of useIntended as a guideline for medical necessity determinations; coverage decisions subject to evidence of coverage, state/federal requirements, and Health Plan administrative policies.
    Policy Summary
    PayerHealth Net
    PolicyAsfotase Alfa (Strensiq) clinical policy
    Policy CodePolicy CP PHAR.328
    Change TypeNo material change
    Effective DateMar 1, 2024
    Next Review DateNov 24, 2024
    Key ActionProvider must submit documentation (office chart notes, lab results or other clinical information) supporting that the member has met all approval criteria.
    SourceLink
    On This Page
    Coverage CriteriaInitial TherapyContinuation / Renewal CriteriaCoding and DosingProvider Actions and RequirementsSite of CareFormulary / Step Therapy RoutingBackgroundDefinitions and Purpose
    Policy revision note4Q2020 annual review updated commercial approval duration; later reviews (4Q2021–4Q2024) noted no significant changes to duration wording.
    • Clinical policy is a guideline — individualized treatment decisions remain the responsibility of the treating provider
    • Submit documentation consistent with medical necessity to support approval requests
    Note

    Formulary / Off‑Label Routing

    For requests for uses that are off‑label or for drugs not on the formulary/PDL, follow the applicable Health Net non‑formulary or off‑label use policies for the member's line of business. Requests for non‑FDA approved indications may be denied without sufficient off‑label documentation per the referenced policies.

    • For formulary drugs: refer to no coverage criteria policies — Commercial: CP.CPA.190; Health Insurance Marketplace: HIM.PA.33; Medicaid: CP.PMN.255
    • For non‑formulary drugs: refer to non‑formulary policies — Commercial: CP.CPA.190; Health Insurance Marketplace: HIM.PA.103; Medicaid: CP.PMN.16
    • For off‑label use documentation requirements: Commercial: CP.CPA.09; Health Insurance Marketplace: HIM.PA.154; Medicaid: CP.PMN.53
    Billing Rule

    Coding Inclusion/Exclusion Disclaimer

    Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up‑to‑date professional coding guidance when submitting claims for reimbursement.

    • Inclusion or exclusion of codes does not guarantee coverage
    • Verify coding with current coding manuals and payer billing guidance prior to claim submission
    Denial Risk

    Non‑Approved Indications

    Requests for indications not FDA‑approved and not addressed in this policy require adequate off‑label documentation of efficacy and safety per the applicable off‑label use policy; lacking sufficient documentation, such requests may be denied.

    • Non‑approved indications may be denied without sufficient off‑label documentation (see CP.CPA.09 / HIM.PA.154 / CP.PMN.53)
    Documentation Required

    Required Clinical Documentation

    Provider must submit chart notes, lab results, genetic testing, and other clinical information to support that the member meets the stated criteria for approval.

    • Office/chart notes documenting clinical manifestations and functional status
    • Relevant laboratory data and genetic testing reports
    • Treatment history and prescribing provider specialty/consultation notes
    DisclaimerThe Health Plan makes no representations or accepts liability for external information used in developing this clinical policy; this policy does not constitute a contract.